- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors.
This study is testing a new medicine, PRS-344/S095012, combined with another treatment, Gazyvaro, for people with solid tumours. It aims to find the right dose and see how safe and effective the combination is.
For: Soild TumorsSpain · France · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
This study compares two treatments for chronic lymphocytic leukaemia (CLL) in patients who haven't had treatment before and have other health issues. It's looking at how well a new combination of medicines works against a standard treatment, aiming to find safer and more effective options.
For: Chronic Lymphocytic Leukemia (CLL)Bulgaria · Estonia · Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 139 CLL: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial).
This study looks at new ways to treat chronic lymphocytic leukaemia (CLL). It combines a medicine called obinutuzumab with venetoclax to see if it helps patients who can't have standard chemotherapy. Researchers want to find out how well it works and if it can clear all signs of the cancer.
For: Chronic lymphocytic leukemiaNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.
For: Chronic Lymphocytic Leukemia (CLL)Spain · France · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)
This study looks at a new drug, Obinutuzumab, for a kidney disease called primary membranous nephropathy. It's for people whose disease hasn’t responded well to a common treatment called rituximab, or if they can’t take rituximab. We want to see how well it works and if it's safe.
For: Primary Membranous NephropathyItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
This study is testing a new combination of medicines (Venclexta, Tecentriq, and Gazyvaro) for adults with Richter Transformation, a type of aggressive cancer linked to chronic lymphocytic leukemia (CLL). Doctors want to see if this treatment is safe and helps shrink the cancer.
For: Richter syndrome of chronic lymphocytic leukemiaItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
This study looks at a new combination of medicines for adults with a type of blood cancer called Diffuse Large B Cell Lymphoma that has come back or is hard to treat. It checks how safe the medicines are and how well they work.
For: Relapsed/Refractory Diffuse Large B Cell LymphomaSpain · France · Germany - AuthorisedTherapeutic exploratory (Phase II)
Obinutuzumab induced decreases of PLA2Rab in MN: a pilot study
This study is looking at a new treatment called Gazyvaro (obinutuzumab) for a kidney disease called primary membranous nephropathy. It aims to see how well the medicine reduces certain antibodies (PLA2R antibodies) that cause the disease, and if it helps improve kidney function and quality of life.
For: Primary membranous nephropathyNetherlands - AuthorisedTherapeutic exploratory (Phase II)
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
This study, called UPROOT, is looking into a new treatment for Sjögren's syndrome using a medicine called Gazyvaro. It aims to see if Gazyvaro can reduce certain immune cells in the blood and affected areas, which might help improve symptoms of Sjögren's syndrome.
For: Sjögren's syndromeNetherlands